Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
关于预计2026年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2026. It includes details about the nature of the transactions, the parties involved, the decision-making and approval process by the board and committees, and compliance with relevant regulations. The document does not contain financial statements or detailed financial performance data but rather focuses on disclosure of anticipated related party dealings and governance around them. It is a regulatory announcement about related party transactions rather than a full financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-12-29 Chinese
国新证券股份有限公司关于云南生物谷药业股份有限公司预计2026年关联交易事项的专项核查意见
Regulatory Filings Classification · 87% confidence The document is a special review opinion (“专项核查意见”) provided by the sponsor (保荐机构) on expected 2026 related-party transactions as part of a securities issuance/listing process. It does not contain full financial statements or an annual/interim report, nor is it an audit report by an auditor. It’s a regulatory compliance filing within the context of an IPO prospectus and does not fit any specific category such as 10-K, IR, ER, AR, etc. Therefore it falls under the general Regulatory Filings (RNS) category.
2025-12-29 Chinese
第五届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the tenth meeting of the fifth board of directors of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references related board committee meetings. The content focuses on board decisions, specifically about anticipated related-party transactions for 2026. There is no financial report, earnings data, or regulatory filing of financial results. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but the actual meeting resolution announcement. Therefore, the classification is MANG with high confidence.
2025-12-29 Chinese
关于收到原实际控制人、原高管刑事裁定书的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from a company regarding the receipt of a criminal ruling involving former controlling persons and executives. It details the legal case, penalties, and the impact on the company. There are no financial statements, earnings data, or management discussion of financial results. The document is a legal proceeding update related to the company, specifically a criminal court ruling and its consequences. This fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification. Therefore, the best classification is LTR with high confidence.
2025-12-21 Chinese
关于已回购股份的出售结果公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the sale of previously repurchased shares by the company. It details the number of shares sold, the sale period, prices, and confirms the completion of the sale plan. It does not contain financial statements or detailed financial analysis but is a disclosure of a transaction involving the company's own shares. This fits the definition of a 'Transaction in Own Shares' filing, which reports on share repurchases or sales by the company itself. The document length is short and focused solely on this transaction, so it is not an annual or interim report or any other type of filing.
2025-12-09 Chinese
关于出售已回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress of selling shares that were previously repurchased. It details the number of shares sold, the timeline, prices, and compliance with regulatory guidelines. The document does not contain financial statements or detailed financial analysis but rather updates on the company's share repurchase and resale activities. This fits the category of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares.
2025-12-01 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.